{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:25:35Z","timestamp":1794000335780,"version":"4.8.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.leukres.2021.106627","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T13:56:47Z","timestamp":1621346207000},"page":"106627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia\/lymphoma: A single-center study"],"prefix":"10.1016","volume":"108","author":[{"given":"Shunichiro","family":"Yasuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8910-0021","authenticated-orcid":false,"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6203-9435","authenticated-orcid":false,"given":"Tatsuya","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Takezaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7966-291X","authenticated-orcid":false,"given":"Satoshi","family":"Kaito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Kurosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1303-5494","authenticated-orcid":false,"given":"Masahiro","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaito","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Shingai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7436-972X","authenticated-orcid":false,"given":"Takashi","family":"Toya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5062-5795","authenticated-orcid":false,"given":"Kazuhiko","family":"Kakihana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Kawamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuteru","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.leukres.2021.106627_bib0005","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993)","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2021.106627_bib0010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2005-04-1754","article-title":"Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol","volume":"107","author":"Vitale","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2021.106627_bib0015","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","article-title":"T-cell acute lymphoblastic leukemia","volume":"2016","author":"Raetz","year":"2016","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"11","key":"10.1016\/j.leukres.2021.106627_bib0020","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/sj.leu.2401555","article-title":"Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study","volume":"13","author":"Pullen","year":"1999","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.leukres.2021.106627_bib0025","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","article-title":"Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2021.106627_bib0030","first-page":"1212","article-title":"The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols","volume":"91","author":"van Grotel","year":"2006","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.leukres.2021.106627_bib0035","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2021.106627_bib0040","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","article-title":"Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study","volume":"99","author":"Annino","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2021.106627_bib0045","first-page":"3983","article-title":"Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience","volume":"93","author":"Wetzler","year":"1999","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2021.106627_bib0050","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2021.106627_bib0055","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.2011.40.8724","article-title":"Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"30","author":"Dunsmore","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2021.106627_bib0060","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ajh.25957","article-title":"Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma. A CAMPUS ALL study","volume":"95","author":"Candoni","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2021.106627_bib0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.24947","article-title":"Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma","volume":"93","author":"Abaza","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.leukres.2021.106627_bib0070","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.leukres.2021.106627_bib0075","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2021.106627_bib0080","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ejh.12722","article-title":"Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment","volume":"96","author":"Bassan","year":"2016","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2021.106627_bib0085","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/PPO.0b013e31826b1232","article-title":"Adult lymphoblastic lymphoma","volume":"18","author":"Portell","year":"2012","journal-title":"Cancer journal (Sudbury, Mass.)"},{"issue":"20","key":"10.1016\/j.leukres.2021.106627_bib0090","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2021.106627_bib0095","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1182\/blood-2002-01-0110","article-title":"Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia","volume":"99","author":"Hoelzer","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2021.106627_bib0100","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1365-2141.2011.08788.x","article-title":"Chromosome abnormalities in advanced stage T-cell lymphoblastic lymphoma of children and adolescents: a report from Japanese Paediatric Leukaemia\/Lymphoma Study Group (JPLSG) and review of the literature","volume":"154","author":"Sekimizu","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2021.106627_bib0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/pbc.20550","article-title":"Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma","volume":"47","author":"Raetz","year":"2006","journal-title":"Pediatr. Blood Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2021.106627_bib0110","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/s41409-018-0184-7","article-title":"Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma","volume":"53","author":"Yang","year":"2018","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.leukres.2021.106627_bib0115","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood-2002-05-1483","article-title":"A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma","volume":"101","author":"Levine","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2021.106627_bib0120","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","article-title":"Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia","volume":"8","author":"Cheson","year":"1990","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2021.106627_bib0125","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.leukres.2021.106627_bib0130","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.leukres.2021.106627_bib0135","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.leukres.2021.106627_bib0140","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/10428194.2016.1193860","article-title":"Stem cell transplantation outcomes in lymphoblastic lymphoma","volume":"58","author":"Brammer","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.leukres.2021.106627_bib0145","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","article-title":"Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2021.106627_bib0150","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.bbmt.2012.07.011","article-title":"Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia","volume":"18","author":"Bakr","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"1","key":"10.1016\/j.leukres.2021.106627_bib0155","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/bmt.2016.194","article-title":"Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes","volume":"52","author":"Brammer","year":"2017","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.leukres.2021.106627_bib0160","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.bbmt.2017.04.003","article-title":"Allogeneic hematopoietic cell transplantation for adult T cell acute lymphoblastic leukemia","volume":"23","author":"Hamilton","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"1","key":"10.1016\/j.leukres.2021.106627_bib0165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3960\/jslrt.56.28","article-title":"Clinical outcomes after allogeneic stem cell transplantation for adult lymphoblastic lymphoma","volume":"56","author":"Makita","year":"2016","journal-title":"J. Clin. Exp. Hematop."},{"issue":"4","key":"10.1016\/j.leukres.2021.106627_bib0170","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28129","article-title":"The effect of graft-versus-host disease on outcomes after allogeneic stem cell transplantation for refractory lymphoblastic lymphoma in children and young adults","volume":"67","author":"Mitsui","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2021.106627_bib0175","doi-asserted-by":"crossref","first-page":"21418","DOI":"10.1038\/s41598-020-78334-x","article-title":"Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies","volume":"10","author":"Morita-Fujita","year":"2020","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.leukres.2021.106627_bib0180","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","article-title":"Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)","volume":"33","author":"Maschmeyer","year":"2019","journal-title":"Leukemia"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2021.106627_bib0185","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"issue":"10","key":"10.1016\/j.leukres.2021.106627_bib0190","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1002\/cncr.10552","article-title":"The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma","volume":"94","author":"Dabaja","year":"2002","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.leukres.2021.106627_bib0195","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2021.106627_bib0200","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019000904","article-title":"Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia","volume":"134","author":"Vogiatzi","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2021.106627_bib0205","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41375-019-0548-z","article-title":"Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell\/CD19\/CD22-negative acute lymphoblastic leukemia","volume":"34","author":"Ofran","year":"2020","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621001284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621001284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:01:36Z","timestamp":1758934896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621001284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":41,"alternative-id":["S0145212621001284"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106627","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia\/lymphoma: A single-center study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106627"}}